Omnicare ’s Unwanted Spotlight Produces Mixed Results

This article gives an overview of both cases, as well as potential implications for compliance officers to pay attention to. Omnicare, the nation’s largest provider of pharmacy services to long-term care facilities, recently has been in the unwanted Government spotlight in two separate cases that produced mixed results. In the first case, the Department of Justice (“DOJ”) announced a $28 million settlement with the company to resolve allegations that the company solicited and received kickbacks from pharmaceutical manufacturer Abbott Laboratories in exchange for promoting Depakote for nursing home patients.  In the second case, the Fifth Circuit Court of Appeals, a mere eleven days later, affirmed a summary judgment decision for the company. The Court of Appeals found that Omnicare’s settlement negotiation and debt collection practices involving its skilled nursing facility (“SNF”) clients were not intended to induce referrals in violation of the Federal False Claims Act (“FCA”). Read Full Article in the December 2016 Issue of Life Science Compliance Update To Read the Full Story, Subscribe, Download a Sample Issue, or Sign In       Related StoriesHas Integrity Become a Commodity? - Warning Signs of Bad Behavior for Compliance ProfessionalsMedical Affairs and Marketing: The Evolving Role of the Compliance OfficerThe Seventeenth Annual PCC: Day 2 Highlights 
Source: Policy and Medicine - Category: American Health Authors: Source Type: blogs